January 2022 "G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers

fruitful research space has led to more than 700 approved drugs over previous decades—but the two-year-old biotech

Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business

Modern drug development approaches include a range of techniques leveraging structural biology, immunology

technologies that stabilize G protein–coupled receptors (GPCRs) to enable the discovery of agonistic biologics

target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics

Therefore, this study aimed to conduct prospective virtual screening and confirm the biological activity

(Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel

It is classified into two types: Sigma-1 (S1R) and Sigma-2 (S2R) based on their biological functions.

Expression is directed by the endogenous mouse promoter and hence occurs in all biologically relevant

, recent developments and use of GPR84 pharmacological tool compounds to study its broader role and biology

Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical

August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a

(NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative

The Boston biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead

July 19, 2022 07:00 AM Eastern Daylight Time BOSTON--Tectonic Therapeutic, Inc. a pre-clinical stage biotechnology Barry Rubenstein as Senior Vice President, People and Culture and Washington Alves as Vice President, Biologics

Cambridge, UK, 22 July 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical

That money has gone to some 60 biotechs, much of it as early funding."

Principal Investigator of the Molecular Pharmacology Research Unit and Professor in the Department of Biochemistry

will gain unique and valuable access to the Sosei Heptares compound library for its industry-leading biology Japan, Cambridge, UK and New York, USA – May 17, 2022 – Sosei Group Corporation, the international biopharmaceutical

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company

South Korea, 28 April 2022 – GPCR therapeutics, Inc., a venture-backed clinical stage international biopharmaceutical

best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations , Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure

Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel

been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately (see biographies

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced

Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing The two companies will combine their expertise to identify GPCR targets and associated biomarkers to

than three decades of experience leading sales and marketing operations for both global and domestic biotechnology